<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-64510</identifier>
<setSpec>1139-9287</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:description xml:lang="en">Aripiprazole is a dopamine partial agonist antipsychotic drug that has just been approved in Europe for its use in the treatment of acute mania and for the prevention of manic episodes in bipolar disorder. Its efficacy in mania is superior to that of placebo, both as monotherapy and as adjunctive therapy, and comparable to that of haloperidol and lithium. From the safety perspective it is remarkable that it is not highly sedative and does not impair the metabolic parameters. The advantages of a non-sedative and metabolically neutral antimanic drug are particularly relevant in the long-term, due to their impact on cognition and quality of life. The experience on its use in routine clinical practice indicates that in order to avoid phenomena such as activation, abrupt worsening or akathisia, it is recommendable to start treatment with low doses and to increase them progressively, especially in those patients who are already receiving other drugs; moreover, it is advisable not to stop abruptly any ongoing treatment, unless there is an emergency, to transiently prescribe a concomitant benzodiazepine, and to maintain the dose that proved efficacious during the short term treatment during maintenance therapy (AU)</dc:description>
<dc:creator>Vieta, E</dc:creator>
<dc:creator>Franco, C</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El aripiprazol es un antipsicótico agonista parcial dopaminérgico que acaba de ser aprobado en Europa para su uso en el tratamiento de la manía aguda y para la prevención de episodios maníacos en el trastorno bipolar. Su eficacia en manía es superior al placebo, tanto en monoterapia como en asociación, y comparable a la de haloperidol y litio, y de su perfil de seguridad destaca la escasa sedación y el respeto de los parámetros metabólicos. Las ventajas de un antimaníaco no sedativo y metabólicamente neutro son especialmente visibles a medio y largo plazo por su potencial impacto en la cognición y la calidad de vida. La experiencia en su utilización en la práctica clínica habitual indica que para evitar fenómenos de activación, reagudización o acatisia, especialmente en pacientes ya tratados previamente con otros fármacos, es recomendable iniciar el tratamiento con dosis bajas, subir progresivamente, no interrumpir bruscamente el tratamiento previo salvo en caso de urgencia, asociar temporalmente una benzodiazepina y mantener las dosis eficaces en fase aguda durante el mantenimiento (AU)</dc:description>
<dc:source>Actas Esp Psiquiatr;36(3): 158-164, mayo-jun. 2008. tab</dc:source>
<dc:identifier>ibc-64510</dc:identifier>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d29542^s22073</dc:subject>
<dc:subject>^d7170^s22073</dc:subject>
<dc:subject>^d14542^s22073</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d13328</dc:subject>
<dc:subject>^d934^s22073</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d8267^s22073</dc:subject>
<dc:subject>^d14542^s22079</dc:subject>
<dc:subject>^d1738^s22057</dc:subject>
<dc:subject>^d1738^s22016</dc:subject>
<dc:type>article</dc:type>
<dc:date>200806</dc:date>
</metadata>
</record>
</ibecs-document>
